Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 144   

Articles published

NVS 98.93 +2.44 (2.53%)
price chart
Here's Why Novartis AG (NVS) Stock Could Fall Today
Novartis AG (ADR) (NYSE:NVS) announced early Monday morning that its drug Gilenya failed to meet its primary endpoint in a Phase III study, called INFORMS, designed to measure the efficacy of the drug in treating primary-progressive multiple sclerosis ...
Novartis Multiple Sclerosis Drug Gilenya Fails Phase III Study  Zacks.com
Novartis' Gilenya Fails To Treat Progressive MS NVS BIIB  Investor's Business Daily
Related articles »  
Novartis AG (ADR) Analyst Rating Update
Analysts at Zacks have given a Neutral rating on Novartis AG (ADR) (NYSE:NVS) with a rank of 3. The counter has received an average rating of 2 from 8 brokerage firms.
Novartis AG (ADR) Receives Analyst Recommendation
Cowen upgraded Novartis to Outperform based on promising pipeline candidates, divestitures of under-performing businesses, clarified generic risks, and attractive valuation.
Novartis AG Raised to Outperform at Cowen and Company (NVS)  sleekmoney
Investor Watch: Novartis AG (ADR) (NYSE:NVS), Whiting Petroleum Corp (NYSE ...
Novartis AG (ADR) (NYSE:NVS) was upgraded to a equal weight rating by analysts at Morgan Stanley. Analysts at Morgan Stanley believe that the company provides prime value to investors going forward and the growth trajectory for the company looks intact ...
Novartis AG Rating Increased to Equal Weight at Morgan Stanley (NVS)  Mideast Time
Related articles »  
Novartis AG Optimistic About 2015; Expects Earnings To Register High Single ...
Novartis AG (ADR) (NYSE: NVS) announced mixed financial and operational results for the fourth quarter of its fiscal year 2014 (4QFY14) as well as the full fiscal year before US markets opened for trading on Tuesday.
Investors Sell on the Strength of Novartis AG (ADR)
Novartis AG (ADR) (NYSE:NVS) managed to stay afloat and traded higher with an addition of 0.45 point or 0.47% at $96.81.
Analyst Price Target on Novartis AG (ADR)
In the latest statement by the brokerage house, Cowen & Company upgrades its outlook on Novartis AG (ADR) (NYSE:NVS).
Novartis AG (ADR) Receives Analyst Rating
Major Brokerage house, Cowen & Company upgrades its ratings on Novartis AG (ADR) (NYSE:NVS). In the latest research report, Cowen & Company raises the target price from $95 per share to $105 per share on the counter.
Novartis AG Upgraded by Cowen and Company to Outperform (NVS)  Intercooler
Related articles »  
Foreign Companies News: Rio Tinto plc (ADR) (RIO), Novartis AG (ADR) (NVS ...
Rio Tinto plc (ADR) (NYSE:RIO), the world's second-biggest mining company, is now seeing iron ore trading close to $100 per metric ton.
Related articles »  
Novartis' (NVS) Signifor Wins EU Approval For Rare Hormonal Disorder
Novartis AG (ADR) (NYSE:NVS) announced before US markets opened for trading Monday that the European Commission has approved its drug Signifor for the treatment of a rare hormonal disorder that is believed to affect about 1-2 in every 10,000 ...
Related articles »